This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). Diabetes Care. 4 Approximately 6.7 million adults in the U.S. NCT05047263.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Medications Medications are often the first line of treatment for cardiomegaly and can include: ACEinhibitors or ARBs , which help lower blood pressure and reduce the workload on the heart. Monitor cholesterol levels and manage conditions like diabetes that can strain the heart. Avoid excessive alcohol and drug use.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Case Description:A 59-year-old male with history of hypertension, diabetes, Hashimoto’s thyroiditis presented with new, progressive shortness of breath. Circulation, Volume 150, Issue Suppl_1 , Page A4142012-A4142012, November 12, 2024. No murmur or extra heart sound were heard, and the lung sounds were normal.
Mean patient age was 55 yrs, 56% (n=575) were women, and comorbid conditions were frequent: hypertension (64.1%), dyslipidemia (46.1%), diabetes (25.7%), documented coronary artery disease (19.3%), previous revascularization (20.6%), previous myocardial infarction (10.1%). Length of stay (LOS) in the CPU to discharge was 10.4
But the rising trends of obesity, diabetes, and cardiovascular disease and the falling trend of activity levels lead me to a dark conclusion: things probably aren’t going to get any better. ACEinhibitors block the angiotensin-converting enzyme to reduce blood pressure. I’m an exercise scientist by training.
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Anyone with diabetes would be prescribed blood sugar lowering medications. With diabetes, the aim is also to reduce heart attacks and strokes… additionally kidney failure, and amputations, and blindness. People at risk of cardiovascular disease would have their cholesterol levels checked. Then, if high, put on statins.
ACEinhibitors, or potassium-sparing diuretics), are particularly susceptible. In today’s case the patient is suffering from diabetic ketoacidosis, which facilitates hydrogen ion shift into the cells in exchange for potassium.
These include ACEinhibitors (and now a medication called Entresto), beta blockers, Mineralocorticoid receptor antagonists and now a new class of anti-diabetic medications called SGLT2 inhibitors and ideally wherever possible the patient should try and take a little of all of them as opposed to taking lots of one and none of the others.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content